morgan stanley glp 1 Eli Lilly Just Got a Huge Vote of Confidence From -- and It's All About Mounjaro Morgan Stanley sees a profound

Description

A Boost for Clinical Trials and Beyond Mark Bagnall, CEO of Phenomix Sciences, highlighted the broader implications: This study underscores the power of predictive tools like MyPhenome to transform how we approach obesity treatmentnot just in the clinic, but in the drug development pipeline

Comparative efficacy and safety of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity or overweight: a systematic review and network meta-analysis

Injection site reactions are another common side effect of GLP-1 RAs

Cummings: There are a lot of hints that the drugs may act in the reward centers of the brain, and those actions may have something to do with why they seem to be associated with lower alcohol and substance abuse and smoking, and other compulsive behaviors like gambling and shopping